Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines... Show more
Milestone Pharmaceuticals holds a distinctive position in cardiovascular medicine as a commercial-stage company with a first-in-class, self-administered therapy. CARDAMYST (etripamil) is the first and only FDA-approved nasal spray enabling patients to convert acute episodes of paroxysmal supraventricular tachycardia (PSVT) to normal rhythm on demand, outside a hospital or clinic setting. This "self-administration" thesis is the foundation of the company's medium-term market positioning, potentially reshaping how episodic cardiac rhythm conditions are managed versus traditional emergency-department or catheter-ablation pathways.
The strategic outlook hinges on execution across three fronts: establishing durable commercial traction and payer access in the United States, demonstrating etripamil's utility in a larger adjacent indication (AFib-RVR), and monetizing international rights through partners. A lean operating model—roughly 40 employees—keeps fixed costs contained but also concentrates execution risk in a single asset. Competitive durability will depend on sustained prescriber adoption, gross-to-net pricing quality, and evidence generation rather than near-term share movement.
Several forward-looking catalysts could meaningfully influence investor sentiment in the coming quarters. The next earnings release, scheduled for November 13, 2026, will be closely watched for prescription growth, realized revenue conversion, and updated payer-coverage metrics. Data presented at the American Heart Association's 2026 Scientific Sessions—showing CARDAMYST converting recurrent PSVT in patients with prior ablation—reinforces the clinical narrative supporting broader adoption.
On the regulatory and pipeline front, continued enrollment in the Phase 3 ReVeRA-301 trial for AFib-RVR represents a potential step-change in addressable market size, while an EMA (European Medicines Agency) marketing application and China's regulatory pathway add geographic diversification. In the nearer term, payer decisions—particularly the transition toward Medicare coverage into 2027—are viewed by analysts as pivotal to the revenue ramp.
Analyst ratings reflect this catalyst-rich setup. The consensus profile skews toward Buy/Strong Buy, though expectations have been recalibrated. Raymond James trimmed its price target to $5 (from $6) while maintaining a Strong Buy, and Wells Fargo adjusted its target to $7 from $8. TD Cowen and H.C. Wainwright have each reiterated Buy ratings with $8 targets. These figures are external analyst expectations, not the company's own guidance, and they underscore a constructive-but-execution-sensitive view.
Milestone's trajectory is shaped by both healthcare-specific dynamics and the broader rate environment. Rising adoption of self-administered and on-demand therapies supports the structural case for CARDAMYST, while pricing and reimbursement policy remain the dominant swing factors. Gross-to-net pricing, denial rates, and copay-support economics directly influence realized revenue, making payer behavior as important as clinical demand.
Macroeconomic conditions matter mainly through financing. As a loss-generating commercial-stage company, Milestone's access to capital—and the cost of any future financing—is sensitive to interest rates and biotech risk appetite. Higher rates historically compress valuations of pre-profitability biotechs and raise dilution risk. Conversely, an improving funding climate could support the capital needed to fund the commercial build-out and AFib-RVR development without an extended runway disruption.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is built to assist users in identifying developing trends, evaluating possible breakouts or reversals, and exploring predictions across a broad universe of tradable instruments. The platform includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking names such as MIST, this tool offers an additional, data-driven lens for monitoring momentum and directional signals as catalysts approach.
Looking toward 2026 and beyond, Milestone's long-term thesis rests on several structural themes. First, market expansion: successfully establishing CARDAMYST as a standard-of-care option for episodic PSVT—and potentially AFib-RVR—would materially widen its commercial opportunity. Second, cost-structure evolution: as revenue scales against a lean operating base, margin sustainability will hinge on efficient commercialization and favorable gross-to-net trends rather than heavy infrastructure spending.
Third, capital allocation: with runway projected into the second half of 2027, management's decisions around funding the AFib-RVR program, commercial expansion, and any future financing will shape dilution risk and sentiment. Fourth, competitive threats: the durable advantages of self-administered, on-demand therapy must be proven against established interventions and any emerging alternatives. Consensus analyst forecasts anticipate meaningful multi-year revenue growth, but those projections are contingent on payer adoption and execution—not guaranteed outcomes.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QMID | 30.13 | 0.10 | +0.35% |
| WisdomTree U.S. MidCap Quality Growth Fund (QMID) | |||
| ACGO | 36.20 | N/A | N/A |
| Hartford Alpha Capture Growth ETF (ACGO) | |||
| SGRW | 24.67 | -0.15 | -0.59% |
| Harbor Active Small Cap Growth ETF | |||
| FXZ | 74.82 | -0.64 | -0.85% |
| First Trust Materials AlphaDEX Fund (FXZ) | |||
| PPLT | 13.50 | -0.21 | -1.53% |
| abrdn Physical Platinum Shares ETF (PPLT) | |||
A.I.dvisor indicates that over the last year, MIST has been loosely correlated with RCUS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To MIST | 1D Price Change % | ||
|---|---|---|---|---|
| MIST | 100% | -20.63% | ||
| RCUS - MIST | 45% Loosely correlated | -1.91% | ||
| VIR - MIST | 41% Loosely correlated | -17.82% | ||
| TSHA - MIST | 41% Loosely correlated | -2.61% | ||
| RCKT - MIST | 41% Loosely correlated | -3.77% | ||
| NAMS - MIST | 40% Loosely correlated | +0.85% | ||
More | ||||
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Indicator entered the oversold zone -- be on the watch for MIST's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for MIST turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.